Which drug is known for being administered as an off-label treatment and has similar outcomes to FDA-approved options?

Bevacizumab is recognized for its off-label use in treating conditions such as wet age-related macular degeneration (AMD) and choroidal neovascularization (CNV). Initially developed and approved to treat colorectal cancer, its ability to inhibit vascular endothelial growth factor (VEGF) has led to its adoption in ophthalmology, despite not being specifically approved for eye diseases. Studies have shown that Bevacizumab demonstrates similar efficacy and safety profiles compared to FDA-approved treatments like Ranibizumab and Brolucizumab for wet AMD, making it a popular alternative due to its lower cost.

While other drugs mentioned, such as Ranibizumab and Brolucizumab, are FDA-approved for conditions like wet AMD and have been extensively studied in clinical trials, Bevacizumab stands out for its widespread off-label use. The consensus in the ophthalmology community acknowledges that its therapeutic outcomes can align closely with those of the approved agents, contributing to its continued use in clinical practice.